FDA Agrees to Expanded Access Program for the BioVentrix® Revivent TC® System for the Treatment of Ischemic Heart Failure

/PRNewswire/ -- BioVentrix®, Inc., a privately held medical device company focused on the development of less invasive therapies to directly treat the dilated...

Related Keywords

New York ,United States ,Florida ,American ,Jerryd Estep ,Jim Dillon ,Prnewswire Bioventrix ,Population Health Sciences ,Icahn School Of Medicine At Mount Sinai ,Bioventrix Inc ,Drug Administration ,Investigational Use Only ,Access Program ,Provide Opportunity ,Treat Additional Patients ,Expanded Access Program ,Less Invasive Ventricular Enhancement ,Bioventrix Revivent ,Co Principal Investigator ,Academic Affairs ,Mount Sinai Heart Health System ,Icahn School ,Mount Sinai ,Cleveland Clinic ,Premarket Approval ,Investigational Use Only In The United ,Bioventrix ,Nc ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Medical Equipment ,Clinical Trials Amp Medical Discoveries ,Fda Approval ,